We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 416.99 -0.2798% AAPL 236.12 0.4766% NVDA 141.89 2.8188% GOOGL 163.9 0.2937% GOOG 165.62 0.3453% AMZN 188.49 -0.2646% META 572.8 -0.6366% AVGO 179.26 -0.3502% TSLA 217.715 -1.3525% TSM 201.3996 0.3086% LLY 907.515 -1.1389% V 287.48 -1.0804% JPM 223.49 -0.8342% UNH 572.61 0.5267% NVO 117.1969 -0.7563% WMT 81.0075 -0.372% LVMUY 132.13 -2.3429% XOM 120.405 0.3291% LVMHF 664.5 -1.9483% MA 515.685 -0.1269%

Gritstone Oncology Inc

Healthcare US GRTS

0.0316USD
-0.0156(33.05%)

Last update at 2024-10-21T18:46:00Z

Day Range

0.030.04
LowHigh

52 Week Range

0.673.33
LowHigh

Fundamentals

  • Previous Close 0.05
  • Market Cap86.86M
  • Volume47177526
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-137.07200M
  • Revenue TTM15.64M
  • Revenue Per Share TTM0.13
  • Gross Profit TTM -91.45800M
  • Diluted EPS TTM-1.25

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -119.68700M -75.08200M -105.31400M -94.43300M -64.77500M
Minority interest - - - - -
Net income -113.12700M -74.95500M -104.61100M -90.92600M -64.77500M
Selling general administrative 28.97M 25.93M 21.41M 19.41M 11.81M
Selling and marketing expenses - - - - -
Gross profit 9.27M 46.72M 4.04M 4.37M 1.19M
Reconciled depreciation 6.56M 6.35M 6.64M 4.75M 3.96M
Ebit -120.42800M -75.20900M -106.01700M -97.94000M -65.58400M
Ebitda -118.45200M -68.86200M -99.37300M -93.19500M -61.62300M
Depreciation and amortization 1.98M 6.35M 6.64M 4.75M 3.96M
Non operating income net other -0.00700M -0.07300M - - -
Operating income -120.42800M -75.20900M -106.01700M -97.94000M -65.58400M
Other operating expenses 129.70M 121.93M 110.05M 102.31M 66.77M
Interest expense 1.24M 0.13M 0.70M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 1.98M 0.13M 0.70M 3.51M 0.81M
Net interest income 0.74M 0.13M 0.70M 3.51M 0.81M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -6.56000M -0.12700M -0.70300M -3.50700M 0.81M
Total revenue 9.27M 46.72M 4.04M 4.37M 1.19M
Total operating expenses 129.70M 121.93M 110.05M 102.31M 66.77M
Cost of revenue - - - 82.90M 54.97M
Total other income expense net 0.74M 0.13M 0.70M 3.51M 0.81M
Discontinued operations - - - - -
Net income from continuing ops -119.69400M -75.15500M -105.31400M -94.43300M -64.77500M
Net income applicable to common shares -119.68700M -75.08200M -105.31400M -94.43300M -64.77500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 177.77M 240.75M 278.11M 221.57M 184.39M
Intangible assets - - - 0.52M 0.58M
Earning assets - - - - -
Other current assets 5.63M 7.01M 0.87M 0.27M 0.29M
Total liab 125.92M 69.97M 62.02M 54.83M 50.05M
Total stockholder equity 51.85M 170.78M 216.09M 166.74M 134.34M
Deferred long term liab - - - - -
Other current liab 14.27M 15.68M 11.04M 8.06M 7.42M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings -659.56100M -521.07100M -401.38400M -326.30200M -220.98800M
Other liab - 0.15M 3.13M 8.62M 9.56M
Good will - - - - -
Other assets - 15.03M 8.36M 23.07M 2.78M
Cash 65.28M 55.50M 93.29M 170.06M 57.41M
Cash and equivalents - - - - -
Total current liabilities 27.34M 34.80M 39.96M 26.99M 19.50M
Current deferred revenue 2.35M 5.13M 17.20M 3.48M 4.96M
Net debt 39.49M -15.18200M -66.86800M -144.95700M -33.91800M
Short term debt 6.90M 5.29M 7.48M 5.87M 2.50M
Short long term debt - - - - -
Short long term debt total 104.78M 40.32M 26.42M 25.10M 23.49M
Other stockholder equity 711.39M 691.91M 617.52M 493.02M 355.29M
Property plant equipment - 21.34M 44.54M 22.11M 50.34M
Total current assets 87.44M 182.88M 220.59M 175.39M 131.27M
Long term investments 0.00000M 4.03M 4.62M - -
Net tangible assets - 170.78M 216.09M 166.74M 134.34M
Short term investments 16.29M 116.39M 108.35M 1.00M 70.37M
Net receivables 0.23M 0.66M 2.37M - 0.48M
Long term debt 40.14M 19.35M - - -
Inventory - 3.31M 15.73M - 2.73M
Accounts payable 3.82M 8.69M 4.23M 9.58M 4.62M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00300M -0.08000M -0.07300M - 0.02M
Additional paid in capital - - - - -
Common stock total equity - 0.02M 0.02M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - -521.07100M -401.38400M -326.30200M -220.98800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.92M 15.03M 8.36M 2.21M 2.19M
Deferred long term asset charges - - - - -
Non current assets total 90.33M 57.88M 57.52M 46.18M 53.12M
Capital lease obligations 64.63M 20.97M 26.42M 25.10M 23.49M
Long term debt total - 19.35M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -7.09200M -112.85200M 69.46M 32.01M -53.44000M
Change to liabilities 6.68M 8.21M 2.56M 0.69M 4.97M
Total cashflows from investing activities -12.96400M -118.55300M 65.95M 15.84M -59.10300M
Net borrowings 18.71M -0.05600M -0.10400M -0.80700M -0.05600M
Total cash from financing activities 83.10M 108.76M 135.80M 74.39M 110.44M
Change to operating activities -11.20800M -9.57800M -2.93600M -1.40300M -1.85300M
Net income -119.68700M -75.08200M -105.31400M -94.43300M -64.77500M
Change in cash -45.81200M -60.47100M 112.65M 5.22M 13.18M
Begin period cash flow 110.58M 171.05M 58.40M 53.17M 40.00M
End period cash flow 64.77M 110.58M 171.05M 58.40M 53.17M
Total cash from operating activities -115.94600M -50.67800M -89.10200M -85.01100M -38.16200M
Issuance of capital stock 64.74M 112.89M 135.91M 75.20M 113.52M
Depreciation 6.56M 6.35M 6.64M 4.75M 3.96M
Other cashflows from investing activities - -0.23800M -0.23800M 32.01M -53.44000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 65.51M 117.21M 10.88M 75.20M 113.52M
Other cashflows from financing activities 18.59M -4.07200M -0.10400M -0.80700M 17.86M
Change to netincome 3.64M 19.42M 3.31M 5.35M 3.00M
Capital expenditures 5.87M 5.46M 3.52M 16.17M 5.66M
Change receivables - - - - -
Cash flows other operating -13.15900M 14.44M 3.82M -0.02200M 15.24M
Exchange rate changes - - - - -
Cash and cash equivalents changes -45.81200M -60.47100M 112.65M 5.22M 13.18M
Change in working capital -24.52700M -1.36400M -4.93100M -5.65500M 20.21M
Stock based compensation 12.56M 10.55M 7.11M 5.30M 3.00M
Other non cash items 9.15M 8.05M 7.51M 6.38M -0.55200M
Free cash flow -121.81800M -56.14100M -92.61700M -101.18400M -43.82500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GRTS
Gritstone Oncology Inc		 -0.0156 33.05% 0.03 - - 5.48 1.73 86.36 -0.906
NVO
Novo Nordisk A/S		 -0.8931 0.76% 117.20 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 117.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.23 0.67% 482.30 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -17.68 1.78% 973.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Gritstone Oncology Inc

5959 Horton Street, EmeryVille, CA, United States, 94608

Key Executives

Name Title Year Born
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. Co-Founder, Pres, CEO & Director 1967
Mr. Erin E. Jones M.S. Exec. VP & COO 1972
Dr. Karin Jooss Ph.D. Exec. VP and Head of R&D 1965
Ms. Vassiliki Economides Exec. VP & CFO 1981
Mr. James Cho Chief Accounting Officer NA
Ms. Stacy Proctor Sr. VP & Head of People NA
Dr. Matthew J. Hawryluk M.B.A., Ph.D. Exec. VP & Chief Bus. Officer 1978
Mr. Vijay Yabannavar Ph.D. Exec. VP & Chief Technical Devel. Officer 1962
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. Co-Founder, President, CEO & Director 1966
Mr. Erin E. Jones M.S. Executive VP & COO 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.